A judge has thrown out a lawsuit against the state of California by three terminally ill residents seeking doctor-prescribed fatal medication.
A new report released Monday by the Washington, D.C.-based Bipartisan Policy Center found that $1.5 trillion invested in research and development over the past 20 years resulted in fewer drugs actually going to market compared to the 1950s.
Chicago-based Swedish Covenant Hospital is expanding its Immediate Care Center program, joining a growing list of hospitals investing in urgent-care operations.
Capella Healthcare, the privately held, Franklin, Tenn.-based chain, will be sold to a real estate investment trust in a $900 million deal. As more care moves to the outpatient setting, hospitals are hoping to find value in their bloated real estate portfolios.
Magellan Health reported Monday that second-quarter earnings fell far below Wall Street's expectations. Results at the managed-care and pharmacy benefits company have trended down in both quarters this year.
Israel's Teva Pharmaceutical Industries said Monday it is purchasing Dublin-based Allergan's generic pharmaceuticals business for $40.5 billion, in what analysts called the largest-ever acquisition by an Israeli company.
Covered California enrollees will see premiums increase 4% in 2016, exchange officials said Monday. The increase is actually slightly less than the 4.2% jump consumers experienced between 2014 and 2015.
An increase in patient volume at Ochsner Health System in New Orleans contributed to a higher operating margin in the first half of 2015 and the system is moving forward with new expansion projects.
The CMS has taken steps to ensure transparency and timely renewal of Medicaid demonstration waivers via new guidance. This comes weeks after facing congressional criticism and scrutiny over its oversight of the program. The agency also announced it's creating new ways for states to use 1115 waivers...
British pharmaceutical giant AstraZeneca plans to sell its thyroid cancer drug Caprelsa to Cambridge, Mass.-based Genzyme in a deal valued at $300 million. It's part of the company's strategy to move away from rare disease offerings and focus on key treatments.